For the Inventor, By the Inventor

Enter assignee name

Paramus, NJ, United States of America

Synaptic Pharmaceutical Corporation

USPTO Granted Patents = 126

% Expired Patents = 13.5

CIPO Patents = 1

Forward Citations = 1,068

Loading Chart...

Loading Chart...

69 inventors (with patents filed for the assignee):

Richard L Weinshank (49 out of 56 patents)

Theresa A Branchek (47 out of 55 patents)

Charles Gluchowski (46 out of 71 patents)

4. Paul R Hartig (29 out of 33 patents)

5. Wai C Wong (23 out of 28 patents)

6. Dhanapalan Nagarathnam (20 out of 61 patents)

7. Yoon T Jeon (20 out of 20 patents)

8. Mohammad R Marzabadi (16 out of 26 patents)

9. Jonathan A Bard (16 out of 23 patents)

10. Carlos C Forray (16 out of 18 patents)

11. George Chiu (15 out of 21 patents)

12. John M Wetzel (14 out of 20 patents)

13. Kelli E Smith (13 out of 16 patents)

14. Mary W Walker (13 out of 15 patents)

15. Bharat Lagu (12 out of 13 patents)

Core Competencies:

Neuropeptide Y

MCH1 Receptor

GALR2 Receptor

Selective Antagonists

Dihydropyrimidines

Benzimidazole Derivatives

Feeding Behavior Modulation

Imidazoline Derivatives

Oxazolidinones

Morpholine Derivatives

Serotonin Receptor

Human Receptors

126 patents: Sort by Forward Citations

1. 7105544 - Substituted alkyl amido piperidines (2006-09-12),

2. 6818445 - Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) (2004-11-16),

3. 6790656 - DNA encoding galanin GALR2 receptors (2004-09-14),

4. 6777426 - Imidazole and imidazoline derivatives and uses thereof (2004-08-17),

5. 6770444 - Methods of identifying or screening for agents that binds the Ob-Re (2004-08-03),

6. 6734182 - Aryl sulfonamides and sulfamide derivatives and uses thereof (2004-05-11),

7. 6727264 - Substituted anilinic piperidines as MCH selective antagonists (2004-04-27),

8. 6727257 - 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines (2004-04-27),

9. 6723741 - Benzimidazoles and benzothiazoles and uses thereof (2004-04-20),

10. 6723552 - DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof (2004-04-20),

11. 6720324 - Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof (2004-04-13),

12. 6713265 - Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) (2004-03-30),

13. 6709831 - DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof (2004-03-23),

14. 6706716 - Compounds specific for the human &agr;1d adrenergic receptor and uses thereof (2004-03-16),

15. 6680323 - Dihydropyrimidines and uses thereof (2004-01-20),

Synaptic Pharmaceutical Corporation, based in Paramus, NJ, specializes in the development of innovative therapeutics targeting neuropeptide receptors. The company focuses on key areas such as Neuropeptide Y, MCH1, and GALR2 receptors, exploring selective antagonists and various chemical derivatives to modulate feeding behavior. Through its advanced research in neurobiology, Synaptic aims to address complex neurological conditions, leveraging its expertise in receptor pharmacology and drug development to create impactful solutions in the healthcare landscape.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

126 Patents

#1 in Paramus, NJ

#142 in New Jersey

#3,078 in US

#6,358 in the World

Paramus, NJ, United States of America

Synaptic Pharmaceutical Corporation

Forward Citations = 1,068

69 inventors:

Richard L Weinshank (49 out of 56 patents)

Theresa A Branchek (47 out of 55 patents)

Charles Gluchowski (46 out of 71 patents)

4. Paul R Hartig (29 out of 33 patents)

5. Wai C Wong (23 out of 28 patents)

Please report any incorrect information to [email protected]

Loading…